Key facts
- GenoPalate’s last known valuation is $21.0M (Oct 2022).
- It has raised $13.3M across 7 recorded rounds; the latest was Seed Round ($250K) in Feb 2026.
- Notable investors include gener8tor, gBETA, Wisconsin Economic Development, BrightStar Wisconsin Foundation, Startup Milwaukee — 6 tracked in total.
- GenoPalate has filed 7 Form Ds with the SEC since 2018, most recently Dec 2024 ($3.0M sold to 4 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 7 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for GenoPalate
Funding rounds
7 roundsAbout GenoPalate
Developer of a genetic data analytics platform designed to empower customers to eat healthy by assessing their genes. The company's platform offers a proprietary analysis of genome-wide nutrigenetic profiles from partnered or third-party labs-collected genomic DNA data to develop a line of digital and physical personalized nutrition products, enabling customers to get a comprehensive report about their distinctive nutrition needs.
- Sector
- Healthcare
- HQ
- Milwaukee, WI, United States
- Founded
- 2016
- Employees
- 13
- Website
- genopalate.com/
- Ownership
- Privately Held (backing)
GenoPalate doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GenoPalate shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GenoPalate in its N-PORT filings yet. We sweep new filings monthly.